Home/ Stocks/ SLNO

Soleno Therapeutics, Inc. Common Stock

SLNO XNAS

$52.95 +0.00 (+0.00%) ▲ 15-min delayed

Open

$52.95

High

$52.96

Low

$52.93

Volume

1.21M

Market Cap

$2.76B

About Soleno Therapeutics, Inc. Common Stock

Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue. The company's reporting segment focused on the development and commercialization of its sole therapeutic product, VYKAT XR.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 182 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$94.60M	$31.38M	$0.60
FY 2025	$190.41M	$20.89M	$0.40
Q3 2025	$66.02M	$26.01M	$0.49
Q2 2025	$32.66M	$-4,708,000	$-0.09

Related Market News

No specific coverage for SLNO yet. Check out our latest market news or earnings calendar.

Get SLNO Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Soleno Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.